CN110643542B - Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof - Google Patents
Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof Download PDFInfo
- Publication number
- CN110643542B CN110643542B CN201911023858.9A CN201911023858A CN110643542B CN 110643542 B CN110643542 B CN 110643542B CN 201911023858 A CN201911023858 A CN 201911023858A CN 110643542 B CN110643542 B CN 110643542B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- allergic asthma
- ccfm1072
- lactobacillus
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 105
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 93
- 208000006673 asthma Diseases 0.000 title claims abstract description 50
- 201000009961 allergic asthma Diseases 0.000 title claims abstract description 41
- 238000006243 chemical reaction Methods 0.000 title abstract description 6
- 239000001963 growth medium Substances 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 241001052560 Thallis Species 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 241000218378 Magnolia Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 35
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract description 28
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 22
- 210000004072 lung Anatomy 0.000 abstract description 19
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract description 15
- 235000019260 propionic acid Nutrition 0.000 abstract description 14
- 102000003816 Interleukin-13 Human genes 0.000 abstract description 12
- 108090000176 Interleukin-13 Proteins 0.000 abstract description 12
- 210000002966 serum Anatomy 0.000 abstract description 12
- 108010002616 Interleukin-5 Proteins 0.000 abstract description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 18
- 241000186606 Lactobacillus gasseri Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 102000000743 Interleukin-5 Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000428 dust Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 229940062713 mite extract Drugs 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000036428 airway hyperreactivity Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- 229910052564 epsomite Inorganic materials 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical group [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof, and belongs to the technical field of microorganisms and medicines. The Lactobacillus reuteri (Lactobacillus reuteri) has the function of relieving allergic asthma, and is specifically represented as follows: (1) the lung inflammatory reaction of allergic asthma mice is obviously reduced; (2) remarkably inhibiting the production of total immunoglobulin IgE in the serum of an allergic asthma mouse; (3) the content of IL-5 in the lung of an allergic asthma mouse is obviously reduced; (4) the content of IL-13 in the lung of an allergic asthma mouse is obviously reduced; (5) obviously increases the content of propionic acid in the intestinal tract of an allergic asthma mouse, so that the Lactobacillus reuteri has great application prospect in preparing products for preventing and/or treating the allergic asthma.
Description
Technical Field
The invention relates to lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof, belonging to the technical field of microorganisms and medicines.
Background
Allergic asthma is a common clinical disease and a difficult disease to treat, and the disease course is delayed and healed, and is mainly characterized in that various inflammatory cells (eosinophils, mast cells, T lymphocytes and the like) infiltrate in the airway, and some inflammatory mediators secreted by the cells amplify inflammatory cascade reaction, increase Airway Hyperreactivity (AHR) and stimulate mucus secretion, so that airway obstruction and airway remodeling are caused. In susceptible patients, the inflammation may cause recurrent wheezing, shortness of breath, chest tightness and/or cough, which may lead to respiratory arrest and respiratory failure, which are complications and endanger the life of the patient.
Asthma prevalence increases year by year in developing countries. Its onset is influenced by many factors, such as exposure route, genetic susceptibility, allergen dose, etc. Studies have shown that 85% of asthmatic patients are often allergic to House Dust Mite (HDM). Allergen enters into body for sensitization, the ratio of Th1/Th2 cells in body is unbalanced, Th0 cells tend to differentiate into Th2 cells, and secretion of Th2 factors such as IL-5 and IL-13 is increased, so that body is in sensitization state. When the organism contacts the allergen again, B cells induce the secreted IgE to be combined with the surfaces of basophils and mast cells, and a series of substances such as histamine, leukotriene and the like are released, so that allergic symptoms are generated. The Th2 type cytokines IL-5 and IL-13 play an important role in initiating and maintaining the pathophysiological response process of asthma.
With the intensive study of intestinal flora, a plurality of studies prove that allergic asthma is related to the disturbance of the intestinal flora, the discovery of intestinal flora of healthy people and patients with allergic asthma is compared, beneficial bacteria in intestinal tracts are reduced, harmful bacteria are increased, metabolites in intestinal tracts are changed, such as the reduction of short-chain fatty acids, and the like, the study detects the concentration of the short-chain fatty acids in feces of patients with allergic asthma, and the discovery shows that the concentrations of propionic acid, butyric acid and isobutyric acid in the intestinal tracts of patients with allergic asthma are obviously reduced compared with the concentrations of the propionic acid, the butyric acid and the isobutyric acid in the intestinal tracts of the patients with allergic asthma, and meanwhile, cytokines interleukin 5 and interleukin 13 at the Th2 type allergic reaction level are in negative. It is marked that propionic acid produced by the metabolism of the intestinal flora is beneficial for reducing Th2 response in allergic asthma.
Currently, the means of treating allergic asthma is usually controlled by drugs including bronchodilators, anti-inflammatory drugs and probiotic formulations. Among them, most of the bronchodilatory drugs and anti-inflammatory drugs are administered by intravenous injection or inhalation, so that the patient's compliance with these drugs is poor, which results in repeated attacks of the patient's disease and severe complications such as emphysema and pulmonary heart disease in the patient over time.
Although the probiotic preparation is relatively safe and healthy, most of the probiotic preparations on the market have the defects of slow effect taking and undefined action relationship because the probiotics such as lactobacillus gasseri, lactobacillus rhamnosus, bifidobacterium animalis and the like which are discovered at present and have the symptom of allergic asthma have poor effect or undefined action effect.
Therefore, a probiotic with strong Th2 response reducing and allergic asthma relieving capabilities is urgently needed to solve the problems of slow effect taking and undefined action relation of the existing probiotic preparation for allergic asthma
Disclosure of Invention
In order to solve the problems, the first object of the invention is to provide a Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 strain, wherein the Lactobacillus reuteri CCFM1072 strain is preserved in Guangdong province microbial culture collection center in 8.8.2019, and the preservation number is GDMCC No.60735, and the preservation address is No. 59 building 5 of Michelia Torrens No. 100 Hospital, Guangzhou city.
The Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 is obtained by separating human excrement from the Lai area of Shandong, the strain is subjected to sequencing analysis, the 16S rRNA sequence of the strain is shown as SEQ ID NO.1, the sequence is subjected to nucleic acid sequence comparison in NCBI, and the result shows that the strain is the Lactobacillus reuteri and is named as the Lactobacillus reuteri CCFM 1072.
The microorganism morphological characteristics of the Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 are as follows: the cells were slightly irregular, rounded-ended Campylobacter, non-motile, non-sporulating.
The second purpose of the invention is to provide the application of the Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 in preparing products for preventing, relieving, improving and/or treating allergic asthma.
In one embodiment, the viable count of Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 in the product is not less than 1 × 106CFU/mL。
In one embodiment, the pharmaceutical product comprises Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072, a pharmaceutical carrier and/or a pharmaceutical excipient.
In one embodiment of the present invention, the drug carrier comprises microcapsules, microspheres, nanoparticles, and liposomes.
In one embodiment of the present invention, the pharmaceutical excipient comprises an excipient and an additive.
In one embodiment of the present invention, the pharmaceutical excipients comprise an anti-adhesive agent, a penetration enhancer, a buffering agent, a plasticizer, a surfactant, an antifoaming agent, a thickener, an encapsulating agent, an absorbent, a humectant, a solvent, a propellant, a solubilizer, a cosolvent, an emulsifier, a colorant, a pH adjuster, a binder, a disintegrant, a filler, a lubricant, a wetting agent, an integrating agent, an osmotic pressure adjuster, a stabilizer, a glidant, a flavoring agent, a preservative, a foaming agent, a suspending agent, a coating material, a flavoring agent, a diluent, a flocculating agent and deflocculating agent, a filter aid, and a release retardant.
In one embodiment of the present invention, the additive comprises microcrystalline cellulose, hydroxypropylmethylcellulose, and refined lecithin.
In one embodiment of the present invention, the dosage form of the pharmaceutical product comprises granules, capsules, tablets, pills or oral liquid.
In one embodiment, the product comprises a food, pharmaceutical or nutraceutical.
In one embodiment, the food product comprises a dairy, soy or fruit and vegetable product produced using a starter culture comprising Lactobacillus reuteri (CCFM 1072).
In one embodiment, the food product is a solid beverage comprising Lactobacillus reuteri (CCFM 1072).
In one embodiment of the present invention, the preparation method of the leavening agent is: inoculating Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 into a culture medium according to the inoculation amount accounting for 2-4% of the total mass of the culture medium, and culturing at 37 ℃ for 18h to obtain a culture solution; centrifuging the culture solution to obtain thalli; washing the thallus with phosphate buffer solution with pH of 7.2 for 3 times, and then resuspending with lyophilized protectant (the mass ratio of lyophilized protectant to thallus is 2:1) to obtain resuspension; and (3) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain the fermentation agent of the Lactobacillus reuteri (Lactobacillus reuteri) CCFM 1072.
In one embodiment of the invention, the medium comprises 87.7% water, 10% skim milk, 0.5% glucose, 1.5% tryptone and 0.3% yeast extract solubles by total mass of the medium.
In one embodiment of the invention, the pH of the medium is 6.8.
In one embodiment of the present invention, the ratio of the skimmed milk powder to maltodextrin to sodium L-glutamate is 8-10: 1.
Has the advantages that:
the invention screens out a Lactobacillus reuteri (CCFM 1072), and the Lactobacillus reuteri (CCFM 1072) has the function of relieving allergic asthma and is specifically embodied as follows:
(1) the lung inflammation score of the allergic asthma mouse is reduced from 3.25 to 1.5;
(2) the production of total immunoglobulin IgE in the serum of an allergic asthma mouse is reduced to 354.38 mu g/mL from 403.19;
(3) the content of IL-5 in the lung of the allergic asthma mouse is reduced from 213.19 to 61.40 pg/mL;
(4) the content of IL-13 in the lung of the allergic asthma mouse is reduced from 1044.90 to 442.50 pg/mL;
(5) the content of propionic acid in the intestinal tract of allergic asthma mice is increased from 5.01 to 7.77 mu mol/g,
therefore, the Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 has great application prospect in preparing products (such as food, medicine or health food and the like) for preventing and/or treating allergic asthma.
Biological material preservation
A strain of Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 is classified and named as Lactobacillus reuteri, is preserved in Guangdong province microorganism strain preservation center in 8.8.2019, has the preservation number of GDMCC No.60735, and has the preservation address of No. 59 floor 5 of Michelia Torresiae No. 100 in Guangzhou city.
Drawings
FIG. 1 shows the pathological lung tissue scores of different groups of experimental mice.
FIG. 2 shows the content of immunoglobulin IgE in the serum of different groups of experimental mice.
FIG. 3 shows the IL-5 content in alveolar lavage fluid of different groups of experimental mice.
FIG. 4 shows the IL-13 content in the vacuolar lavage fluid of different groups of experimental mice.
FIG. 5 shows the content of propionic acid in intestinal tract of different groups of experimental mice.
Detailed Description
MRS solid medium (g/L): 10g/L of peptone, 10g/L of beef extract, 20g/L of glucose, 2g/L of sodium acetate, 5g/L of yeast powder and 2g/L, K of diammonium hydrogen citrate2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO40.05g/L, Tween 801 mL/L, agar 20g/L and cysteine hydrochloride 0.5 g/L.
MRS liquid medium (g/L): 10g/L of peptone, 10g/L of beef extract, 20g/L of glucose, 2g/L of sodium acetate, 5g/L of yeast powder and 2g/L, K of diammonium hydrogen citrate2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05gL, Tween 801 mL/L and cysteine hydrochloride 0.5 g/L.
The detection methods referred to in the following examples are as follows:
the detection method of viable count comprises the following steps: the national standard GB 4789.35-2016 food safety national standard food microbiology detection of lactobacillus is adopted.
And (3) an acidity detection method: the national standard GB 431334-.
The strains in the examples are described in patent application publication No. CN 109628359A; lactobacillus reuteri l.reuteri1 and l.reuteri2 are strains isolated by the same method.
Example 1: screening and identification of lactobacillus reuteri
The method comprises the following specific steps:
1. screening:
taking human excrement from Laizhou Shandong as a sample, pretreating the sample, storing the pretreated sample in 30% glycerol at-80 ℃, taking out and unfreezing the sample, uniformly mixing the sample, sucking 0.5mL of the sample, adding the sample into 4.5mL of the sample, performing gradient dilution by using 0.9% physiological saline, selecting a proper gradient dilution liquid, coating the gradient dilution liquid on an MRS solid culture medium, culturing the gradient dilution liquid at 37 ℃ for 48h, selecting a typical bacterial colony, streaking and purifying the typical bacterial colony on the MRS solid culture medium, selecting a single bacterial colony, transferring the single bacterial colony to the MRS liquid culture medium for enrichment, and preserving the single bacterial colony by using 30% glycerol to obtain a strain CCFM 1072.
2. And (3) identification:
the 16S rDNA of the CCFM1072 is amplified and sequenced, the sequence is compared with the nucleotide sequence in NCBI, and the result shows that the strain is Lactobacillus reuteri and is named as Lactobacillus reuteri CCFM 1072.
Example 2: culture of Lactobacillus reuteri
The method comprises the following specific steps:
lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 is inoculated into an MRS solid culture medium and cultured for 48 hours at 37 ℃, the bacterial colony is observed and the thallus is observed under a microscope, and the bacterial colony is milk white, irregular, round and convex and smooth, the shape of the thallus is a slightly irregular and round bent bacillus with a tail end, and the single, paired and small clusters exist usually.
Inoculating Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 into an MRS liquid culture medium, culturing at 37 ℃ for 18h, transferring into a fresh MRS liquid culture medium, culturing under the same conditions for 18h, centrifuging the thallus for 15min at 6000g, washing the thallus with 0.9% physiological saline, centrifuging again for 10min at 6000g to obtain the thallus, resuspending the thallus with 30% sucrose solution, and freezing at-80 ℃ for later use.
Example 3: effect of Lactobacillus reuteri on pulmonary inflammation in allergic asthma mice
The method comprises the following specific steps:
the SPF-grade BALB/c female mice of 6 weeks old are divided into 5 groups, namely a normal group, a model group and an experimental group, wherein the experimental group comprises a CCFM1072 prevention group of Lactobacillus gasseri CCFM1072, an L.reuteri1 prevention group of Lactobacillus gasseri 1 and an L.reuteri2 prevention group of Lactobacillus gasseri 2, 6 mice in each group are bred in the center of experimental animals of south Jiangtian university and fed with common feed, the constant temperature is 21-26 ℃, the humidity is 40-70%, the noise is less than or equal to 60dB, and the animal illumination is 15-20LX (all animal experimental procedures are examined and approved by the university of animal welfare and ethics administration of south Jiangtian).
The experiment was performed for 6 weeks (5 days per week), and the model was made at 2-6 weeks, and the model group and the experimental group mice were anesthetized with 25. mu.g/10. mu.L of HDM (house dust mite extract) per day, and the normal group was treated with 10. mu.L of sterile physiological saline alone as a control.
In 1-6 weeks, the experimental group is gavaged with 0.25mL per day (viable count is 1X 10)9CFU), normal and model groups gavage only 0.25mL sterile saline as control, all groups being free to drink and ingest.
After the experiment is finished, the mouse is killed by anesthesia, the thoracic cavity is dissected, the agarose solution is injected into the left lung of the mouse, the left lung is taken out and placed in a 4% paraformaldehyde solution for fixation, paraffin embedding and HE staining are carried out, the left lung is sent to a pathology department for lung inflammation degree evaluation, and the inflammation degree evaluation result is shown in figure 1.
As shown in fig. 1, after mice were fed with the strain CCFM1072 of the present invention, inflammatory cell infiltration was significantly reduced and lung histopathological score was reduced by 54%, which is significantly lower than that of the model group (p < 0.05) and 46% lower than that of the l.reuteri1 and l.reuteri2 groups, which is closer to the blank group, indicating that the l.reuteri CCFM1072 reduces the inflammatory response of the lungs of asthmatic mice.
The experimental results show that compared with L.reuteri1 and L.reuteri2, the Lactobacillus reuteri CCFM1072 can obviously improve the pulmonary inflammation of asthmatic mice and relieve asthma symptoms.
Example 4: effect of Lactobacillus reuteri on Total IgE in serum of allergic asthma mice
The method comprises the following specific steps:
the SPF-grade BALB/c female mice of 6 weeks old were divided into 6 groups, which were a normal group, a model group, and an experimental group, respectively, wherein the experimental group included CCFM1072 prevention group of lactobacillus gasseri CCFM1072, l.reuteri CCFM1040 prevention group of lactobacillus gasseri CCFM1040, l.reuteri1 prevention group of lactobacillus reuteri1, and l.reuteri2 prevention group of lactobacillus gasseri 2, and 6 animals per group were housed in the center of experimental animals of south of the river university, fed with a common feed, kept at a constant temperature of 21-26 ℃, humidity of 40-70%, noise of 60dB or less, and animal illuminance of 15-20LX (all animal experimental procedures were reviewed and approved by the animal welfare and ethics administration committee of south of the river university).
The experiment was performed for 6 weeks (5 days per week), and the model was made at 2-6 weeks, and the model group and the experimental group mice were anesthetized with 25. mu.g/10. mu.L of HDM (house dust mite extract) per day, and the normal group was treated with 10. mu.L of sterile physiological saline alone as a control.
In 1-6 weeks, the experimental group is gavaged with 0.25mL per day (viable count is 1X 10)9CFU), normal and model groups gavage only 0.25mL sterile saline as control, all groups being free to drink and ingest.
After the experiment, anesthetizing the mouse, collecting blood by eyeballs, standing for 2h, centrifuging at 3000rpm of a centrifuge for 10min, collecting serum in a clean centrifuge tube, and freezing and storing at-20 ℃.
The Total IgE content in the serum is detected by a Total IgE ELISA kit, and the detection result is shown in figure 2.
As shown in figure 2, after the strain CCFM1072 of the invention is fed, the content of the total IgE in the blood serum of the mice is reduced to 354 mug/ml which is obviously lower than that of the model group to 403 mug/ml (p is less than 0.05), the content of the total IgE in the blood serum of the mice is equivalent to that of the blank group to 344 mug/ml, the content of the total IgE in the blood serum is superior to that of the L.reuteri1 to 365 mug/ml, and the content of the L.reuteri2 to 394 mug/ml and the content of the L.reuteri CCFM1040 to 410 mug/ml which are not obviously different from that of the model group.
The experimental results show that the lactobacillus reuteri CCFM1072 can obviously reduce the total IgE in the serum of an asthmatic mouse and improve anaphylactic reaction, but the lactobacillus reuteri L.reuteri2 and L.reuteri CCFM1040 have no effect.
Example 5: effect of Lactobacillus reuteri on IL-5 in alveolar lavage fluid of mice with allergic asthma
The method comprises the following specific steps:
the SPF-grade BALB/c female mice of 6 weeks old were divided into 6 groups, which were a normal group, a model group, and an experimental group, respectively, wherein the experimental group included l.reuteri CCFM 1040-prevention group of lactobacillus gasseri CCFM1040, CCFM 1072-prevention group of lactobacillus reuteri CCFM1072, l.reuteri 1-prevention group of lactobacillus gasseri 1, and l.reuteri 2-prevention group of lactobacillus gasseri 2, and 6 animals per group were housed in the center of experimental animals of south of the river, fed with a common feed, kept at a constant temperature of 21-26 ℃, humidity of 40-70%, noise of 60dB or less, and animal illuminance of 15-20LX (all animal experimental procedures were reviewed and approved by the animal welfare and ethics administration committee of south of the river).
The experiment was performed for 6 weeks (5 days per week), and the model was made at 2-6 weeks, and the model group and the experimental group mice were anesthetized with 25. mu.g/10. mu.L of HDM (house dust mite extract) per day, and the normal group was treated with 10. mu.L of sterile physiological saline alone as a control.
In 1-6 weeks, the experimental group is gavaged with 0.25mL per day (viable count is 1X 10)9CFU), normal and model groups gavage only 0.25mL sterile saline as control, all groups being free to drink and ingest.
After the experiment, the mouse is killed by anesthesia, placed on an anatomical plate, the head and four are fixed, the chest and the neck are dissected, the trachea and the two lungs of the mouse are exposed, the right lung is ligated, the trachea cannula is performed by an indwelling needle, 0.3mL precooled PBS is absorbed by a 1mL syringe, the left lung of the mouse is lavaged for 3 times, the recovery amount is more than or equal to 80%, and the lavaging liquid is collected in a clean Eppendorf tube. Collecting supernatant in a centrifuge at 4 deg.C and 1000rpm for 5min, subpackaging in Eppendorf tube, freezing at-20 deg.C, detecting IL-5 content in alveolar lavage fluid by ELISA kit, and the detection result of IL-5 content in alveolar lavage fluid is shown in FIG. 3,
as shown in figure 3, after mice are fed with the strain CCFM1072 of the invention, the content of IL-5 in alveolar lavage fluid is significantly reduced by 71 percent (p is less than 0.05) compared with a model group, and has no significant difference with a normal group, and is respectively reduced by 60 percent and 40 percent better than CCFM1040 and L.reuteri2, which indicates that the strain of the invention can inhibit Th2 reaction; the IL-5 content in the pulmonary alveolar lavage fluid of the L.reuteri1 group is not obviously different from that of the model group, and is only reduced by 13 percent.
Combining the above experimental results, lactobacillus reuteri CCFM1072 can significantly down-regulate typical Th 2-related cytokines in alveolar lavage fluid of asthmatic mice to normal level, and is significantly better than the other three strains of lactobacillus reuteri CCFM1040, l.reuteri1 and l.reuteri 2.
Example 6: effect of Lactobacillus reuteri on IL-13 in alveolar lavage fluid of mice with allergic asthma
The method comprises the following specific steps:
the SPF-grade BALB/c female mice of 6 weeks old are divided into 5 groups, namely a normal group, a model group and an experimental group, wherein the experimental group comprises a CCFM1072 prevention group of Lactobacillus gasseri CCFM1072, an L.reuteri1 prevention group of Lactobacillus gasseri 1 and an L.reuteri2 prevention group of Lactobacillus gasseri 2, 6 mice in each group are bred in the center of experimental animals of south Jiangtian university and fed with common feed, the constant temperature is 21-26 ℃, the humidity is 40-70%, the noise is less than or equal to 60dB, and the animal illumination is 15-20LX (all animal experimental procedures are examined and approved by the university of animal welfare and ethics administration of south Jiangtian).
The experiment was performed for 6 weeks (5 days per week), and the model was made at 2-6 weeks, and the model group and the experimental group mice were anesthetized with 25. mu.g/10. mu.L of HDM (house dust mite extract) per day, and the normal group was treated with 10. mu.L of sterile physiological saline alone as a control.
In 1-6 weeks, the experimental group is gavaged with 0.25mL per day (viable count is 1X 10)9CFU), normal and model groups gavage only 0.25mL sterile saline as control, all groups being free to drink and ingest.
After the experiment, the mouse is killed by anesthesia, placed on an anatomical plate, the head and four are fixed, the chest and the neck are dissected, the trachea and the two lungs of the mouse are exposed, the right lung is ligated, the trachea cannula is performed by an indwelling needle, 0.3mL precooled PBS is absorbed by a 1mL syringe, the left lung of the mouse is lavaged for 3 times, the recovery amount is more than or equal to 80%, and the lavaging liquid is collected in a clean Eppendorf tube. Collecting supernatant in a centrifuge at 4 deg.C and 1000rpm for 5min, subpackaging in Eppendorf tubes, freezing at-20 deg.C, and detecting IL-13 content in alveolar lavage fluid by ELISA kit, wherein the detection result of IL-13 content in alveolar lavage fluid is shown in FIG. 4.
As shown in FIG. 4, after mice were fed with the strain CCFM1072 of the present invention, the IL-13 content in alveolar lavage fluid was reduced by 58%, which was significantly reduced (p < 0.05) compared to the model group, and was not significantly different from the normal group, indicating that the strain of the present invention was able to suppress the Th2 response; and the content of IL-13 in the alveolar lavage fluid of the L.reuteri1 and L.reuteri2 groups is reduced by only 15 percent and 37 percent, and has no significant difference with the model group.
In combination with the above experimental results, lactobacillus reuteri CCFM1072 can significantly reduce the typical Th 2-related cytokine up-regulated in alveolar lavage fluid of asthmatic mice to normal level, especially reduce the IL-13 level which can stimulate airway epithelial cells to produce a large amount of mucus, and is significantly better than the other two strains of lactobacillus reuteri l.reuteri1 and l.reuteri 2.
Example 7: effect of Lactobacillus reuteri on propionic acid in intestinal tract of allergic asthma mice
The method comprises the following specific steps:
the SPF-grade BALB/c female mice of 6 weeks old were divided into 6 groups, namely a normal group, a model group and an experimental group, wherein the experimental group comprises a CCFM1072 prevention group of Lactobacillus gasseri CCFM1072, a L.reuteri CCFM1040 prevention group of Lactobacillus gasseri CCFM1040, a L.reuteri1 prevention group of Lactobacillus gasseri 1 and a L.reuteri2 prevention group of Lactobacillus gasseri 2, and 6 animals in each group were bred in the center of the Experimental animals of south Jiangnan university, fed with a common feed, kept at a constant temperature of 21-26 ℃, a humidity of 40-70%, a noise of 60dB or less, and an animal illuminance of 15-20LX (all animal experimental procedures were examined and approved by the animal welfare and ethics administration Committee of south Jiangnan university).
The experiment was performed for 6 weeks (5 days per week), and the model was made at 2-6 weeks, and the model group and the experimental group mice were anesthetized with 25. mu.g/10. mu.L of HDM (house dust mite extract) per day, and the normal group was treated with 10. mu.L of sterile physiological saline alone as a control.
In 1-6 weeks, the experimental group is gavaged with 0.25mL per day (viable count is 1X 10)9CFU), normal and model groups gavage only 0.25mL sterile saline as control, all groups being free to drink and ingest.
After the experiment was completed, the mice were anesthetized, the abdominal cavity was dissected, the cecum contents were taken out in a clean centrifuge tube and frozen at-20 deg.C
The content of propionic acid in the caecum content was measured by GC-MS, and the results are shown in FIG. 5, and the average content (μ M/g) of each propionic acid group: blank 4.05, model 5.01, CCFM 10727.77, CCFM 10403.87, l.reuteri 15.35, l.reuteri 23.12.
As shown in fig. 5, after mice were fed with the strain CCFM1072 of the present invention, the content of propionic acid in cecum content was significantly increased by 55% (p < 0.05) compared to the model group, which is significantly higher than that of blank and model groups, while lactobacillus reuteri l.reuteri2 group did not show significant increase, and CCFM1040 and l.reuteri1 groups were decreased by 50% and 42%, respectively. The strain CCFM1072 of the invention can promote the production of propionic acid in intestinal tract.
In combination with the above experimental results, lactobacillus reuteri CCFM1072 significantly up-regulated the propionic acid content in short chain fatty acids. Lactobacillus reuteri CCFM1072 is significantly superior to l.reuteri1 and l.reuteri2 in promoting the intestinal production of propionic acid.
Example 8: preparation of solid beverage containing lactobacillus reuteri CCFM1072
Inoculating Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 into a culture medium according to the inoculation amount accounting for 3 percent of the total mass of the culture medium, and culturing at 37 ℃ for 18 hours to obtain a culture solution; centrifuging the culture solution to obtain thalli; cleaning the thallus with phosphate buffer solution with pH of 7.2 for 3 times, and then re-suspending with trehalose lyophilized protectant with trehalose concentration of 100g/L (mass ratio of lyophilized protectant to thallus is 2:1) to obtain re-suspension; and (3) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 powder.
Will contain 109Mixing the powder of the CFU Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 bacteria with maltodextrin, wherein the total mass of the powder of the CCFM1072 bacteria and the maltodextrin is 1 g, and obtaining the solid beverage rich in the Lactobacillus reuteri (Lactobacillus reuteri) CCFM 1072.
Taking 10g (equivalent to a total irrigation 10)10CFU) the solid beverage containing the Lactobacillus reuteri CCFM1072 is dissolved again by normal saline, the volume is constant to 20 ml, each mouse is filled with 200 microliters of the normal saline every day for two weeks, the content of total IgE in the serum of the mouse with allergic asthma, inflammatory cell infiltration in lung tissues and the production of inflammatory cytokines can be effectively reduced, the content of propionic acid in intestinal tracts is improved, and the solid beverage has excellent effect of relieving the allergic asthma.
Example 9: preparation of cow milk containing Lactobacillus reuteri CCFM1072
The method comprises the following specific steps:
inoculating Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 into a culture medium according to the inoculation amount accounting for 3 percent of the total mass of the culture medium, and culturing at 37 ℃ for 18 hours to obtain a culture solution; centrifuging the culture solution to obtain thalli; washing the bacteria with phosphate buffer solution with pH of 7.2 for 3 times, and suspending with trehalose lyophilized protectant with trehalose concentration of 100g/L until the bacteria concentration reaches 1 × 1010CFU/mL to obtain a bacterial suspension; placing the suspension at 37 deg.C for 60min for pre-culturing, and lyophilizing by lyophilization method to obtain Lactobacillus reuteri CCFM1072 leaven; wherein, the cultureThe culture medium comprises 87.7 percent of water, 10 percent of enzyme hydrolysis skim milk, 0.5 percent of glucose, 1.5 percent of tryptone and 0.3 percent of yeast extract solution by mass; the pH of the medium was 6.8;
sterilizing skim milk at 95 deg.C for 20min, cooling to 4 deg.C, adding Lactobacillus reuteri CCFM1072 starter to make viable bacteria concentration of Lactobacillus reuteri CCFM1072 in skim milk reach 1 × 109CFU/mL, and refrigerating at 4 deg.C to obtain cow milk containing viable Lactobacillus reuteri CCFM 1072.
200 microliter of cow milk containing live lactobacillus reuteri CCFM1072 bacteria is taken to perform intragastric administration on the mouse for 3 weeks continuously, so that the content of total IgE in serum of the mouse with allergic asthma, inflammatory cell infiltration in lung tissues and inflammatory cytokine production can be effectively reduced, the content of propionic acid in intestinal tracts is increased, and the cow milk has a good effect on relieving the allergic asthma.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
SEQUENCE LISTING
<110> university of south of the Yangtze river
<120> Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1065
<212> DNA
<213> Lactobacillus reuteri
<400> 1
gcaaatttgt tccgccttag gcggctccct ccataaaggt taggccaccg actttgggcg 60
ttacaaactc ccatggtgtg acgggcggtg tgtacaaggc ccgggaacgt attcaccgcg 120
gcatgctgat ccgcgattac tagcgattcc gacttcgtgt aggcgagttg cagcctacag 180
tccgaactga gaacggcttt aagagattag cttactctcg cgagtttgcg actcgttgta 240
ccgtccattg tagcacgtgt gtagcccagg tcataagggg catgatgatc tgacgtcgtc 300
cccaccttcc tccggtttgt caccggcagt ctcactagag tgcccaactt aatgctggca 360
actagtaaca agggttgcgc tcgttgcggg acttaaccca acatctcacg acacgagctg 420
acgacgacca tgcaccacct gtcattgcgt ccccgaaggg aacgccttat ctctaaggtt 480
agcgcaagat gtcaagacct ggtaaggttc ttcgcgtagc ttcgaattaa accacatgct 540
ccaccgcttg tgcgggcccc cgtcaattcc tttgagtttc aaccttgcgg tcgtactccc 600
caggcggagt gcttaatgcg ttagctccgg cactgaaggg cggaaaccct ccaacaccta 660
gcactcatcg tttacggcat ggactaccag ggtatctaat cctgttcgct acccatgctt 720
tcgagcctca gcgtcagttg cagaccagac agccgccttc gccactggtg ttcttccata 780
tatctacgca ttccaccgct acacatggag ttccactgtc ctcttctgca ctcaagtcgc 840
ccggtttccg atgcacttct tcggttaagc cgaaagcttt cacatcagac ctaagcaacc 900
gcctgcgctc gctttacgcc caataaatcc ggataacgct tgccacctac gtattaccgc 960
ggctgctggc acgtagtagc cgtgactttc tggttggata ccgtcactgc gtgaacagtt 1020
actctcacgc acgtcttctc aacaacagag ctttacgagc cgaaa 1065
Claims (7)
1. The Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 is characterized in that the Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 is preserved in Guangdong province microbial strain preservation center in 8.8.2019, and the preservation number is GDMCC No.60735, and the preservation address is No. 59 building 5 of Michelia Torrens No. 100, Guangzhou city.
2. Use of Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 according to claim 1 for the preparation of a product for the prevention, alleviation, amelioration and/or treatment of allergic asthma; the product is a food and/or a pharmaceutical product.
3. The use according to claim 2, wherein the viable count of Lactobacillus reuteri (CCFM 1072) in the product is not less than 1 x 106CFU/mL。
4. A composition comprising the Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 of claim 1.
5. The composition of claim 4, wherein the composition is a pharmaceutical composition comprising a pharmaceutical carrier and/or a pharmaceutical excipient.
6. Food product comprising a Lactobacillus reuteri (Lactobacillus reuteri) CCFM1072 according to claim 1.
7. A starter is characterized in that the preparation method comprises the following steps: inoculating the lactobacillus reuteri of claim 1 into a culture medium according to an inoculation amount accounting for 2-4% of the total mass of the culture medium, culturing at 35-37 ℃ for 12-24 h, collecting thalli, re-suspending with a freeze-drying protective agent, and freeze-drying by a vacuum freezing method to obtain the lactobacillus reuteri starter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911023858.9A CN110643542B (en) | 2019-10-25 | 2019-10-25 | Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911023858.9A CN110643542B (en) | 2019-10-25 | 2019-10-25 | Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110643542A CN110643542A (en) | 2020-01-03 |
CN110643542B true CN110643542B (en) | 2021-01-29 |
Family
ID=68994724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911023858.9A Active CN110643542B (en) | 2019-10-25 | 2019-10-25 | Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110643542B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113073066A (en) * | 2021-04-16 | 2021-07-06 | 北京华元生物技术研究院 | Lactobacillus reuteri and application, composition, medicine and food thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021146316A1 (en) * | 2020-01-13 | 2021-07-22 | Scioto Biosciences, Inc. | Methods for treating or ameliorating autism and related disorders |
CN111991428A (en) * | 2020-06-12 | 2020-11-27 | 郑州和合生物工程技术有限公司 | Probiotic composition with asthma improving effect and preparation method thereof |
CN114717127B (en) * | 2021-03-31 | 2023-08-29 | 青岛蔚蓝生物股份有限公司 | Lactobacillus reuteri for preventing and relieving allergic asthma symptoms and application thereof |
CN117165465A (en) * | 2021-08-24 | 2023-12-05 | 上海市第一人民医院 | Lactobacillus plantarum strain for improving intestinal barrier function and application thereof |
CN114410502B (en) * | 2021-12-06 | 2023-06-23 | 安徽医科大学 | Lactobacillus reuteri MRD01 and application thereof |
CN117982598B (en) * | 2024-04-03 | 2024-06-21 | 哈尔滨葵花药业有限公司 | Lactobacillus reuteri Glory LR15 composition capable of regulating obesity type asthma and application thereof |
CN118308246A (en) * | 2024-04-03 | 2024-07-09 | 哈尔滨葵花药业有限公司 | Lactobacillus reuteri Glory LR15, and composition and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101939411A (en) * | 2008-02-06 | 2011-01-05 | 宝洁公司 | Compositions methods and kits for enhancing immune response to a respiratory condition |
CN105586299A (en) * | 2016-03-14 | 2016-05-18 | 青岛东海药业有限公司 | Lactobacillus acidophilus preparation and application thereof |
WO2017152137A8 (en) * | 2016-03-04 | 2018-09-07 | The Regents Of The University Of California | Microbial consortium and uses thereof |
CN109628359A (en) * | 2019-02-22 | 2019-04-16 | 江南大学 | One plant of lactobacillus reuteri that can be relieved allergic asthma and its application |
-
2019
- 2019-10-25 CN CN201911023858.9A patent/CN110643542B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101939411A (en) * | 2008-02-06 | 2011-01-05 | 宝洁公司 | Compositions methods and kits for enhancing immune response to a respiratory condition |
WO2017152137A8 (en) * | 2016-03-04 | 2018-09-07 | The Regents Of The University Of California | Microbial consortium and uses thereof |
CN105586299A (en) * | 2016-03-14 | 2016-05-18 | 青岛东海药业有限公司 | Lactobacillus acidophilus preparation and application thereof |
CN109628359A (en) * | 2019-02-22 | 2019-04-16 | 江南大学 | One plant of lactobacillus reuteri that can be relieved allergic asthma and its application |
Non-Patent Citations (2)
Title |
---|
Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice;Forsythe P 等;《Am J Respir Crit Care Med》;20070630;第561-569页,参见全文 * |
口服6 种益生菌的混合制剂对哮喘小鼠气道炎症的影响及其机制;马婧一 等;《山西医科大学学报》;20180630;第596-601页,参见全文 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113073066A (en) * | 2021-04-16 | 2021-07-06 | 北京华元生物技术研究院 | Lactobacillus reuteri and application, composition, medicine and food thereof |
Also Published As
Publication number | Publication date |
---|---|
CN110643542A (en) | 2020-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110643542B (en) | Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof | |
CN109628359B (en) | Lactobacillus reuteri capable of relieving allergic asthma and application thereof | |
CN113073066B (en) | Lactobacillus reuteri and application, composition, medicine and food thereof | |
CN112402459B (en) | Application of clostridium pralatum in relieving allergic asthma and rhinitis Th2 reaction | |
CN110643541B (en) | Lactobacillus casei capable of adjusting Th2/Th1 balance of allergic asthma and application thereof | |
CN110452842B (en) | Bifidobacterium lactis nbk-W13 and application thereof | |
CN114806980B (en) | Culture medium for culturing living biological medicine and application thereof | |
US11369648B2 (en) | Probiotic mixed preparation with anti-influenza ability and application thereof | |
CN113881597B (en) | Lactobacillus reuteri capable of improving indole acrylic acid to regulate specific IgE | |
CN114231470A (en) | Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof | |
CN115505551B (en) | Lactobacillus helveticus and application thereof in preventing or treating nephritis | |
CN115093999B (en) | Clostridium praecox capable of improving blood lipid disorders and application thereof | |
CN115074276B (en) | Clostridium praecox capable of relieving non-alcoholic fatty liver disease and application thereof | |
CN117025489B (en) | Bifidobacterium animalis subspecies VB315 and application thereof | |
CN112239739B (en) | Lactobacillus plantarum capable of relieving ETEC (enterotoxigenic enterobacteria) induced diarrhea and application thereof | |
CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
CN114657100B (en) | Lactobacillus pentosus capable of relieving pathological characteristics of influenza virus infected mice and application thereof | |
CN113913330B (en) | Lactobacillus plantarum for regulating OVA-specific IgE and application thereof | |
CN113041266B (en) | Lactobacillus casei for improving pathological features of psoriasis-like mice and application thereof | |
CN113005066B (en) | Compound bifidobacterium preparation for resisting allergy, increasing immunity, reducing blood sugar and fat and losing weight and preparation method thereof | |
CN112812989B (en) | Bifidobacterium adolescentis capable of relieving psoriasis and application thereof | |
CN110141583B (en) | Application of lactobacillus kefir M3 in bacteriostasis and active ingredient of medicament for treating type II diabetes | |
CN111172054B (en) | Lactobacillus casei combined preparation and application thereof | |
CN115109718B (en) | Enterococcus faecium strain and application thereof | |
CN114317310B (en) | Antiallergic bifidobacterium infantis preparation and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |